<DOC>
	<DOCNO>NCT00698906</DOCNO>
	<brief_summary>This study evaluate immunogenicity safety different formulation HBV-MPL vaccine administer accord 2-dose schedule compare Engerix™-B administered accord 3-dose schedule order determine optimal dose component candidate HBV-MPL vaccine administer 0 6 month</brief_summary>
	<brief_title>Comparing Immunogenicity Safety Different Formulations HBV-MPL Vaccine With Engerix™-B Adults Aged 19-40</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age : 19 40 year old . Good physical condition establish clinical examination history take time entry . Female participant risk become pregnant contraceptive programme necessary study period . Written inform consent obtain subject Positive titre screen antihepatitis antibody . Elevated serum liver enzymes . History significant persisting hematologic , hepatic , renal , cardiac respiratory disease . Any acute disease moment entry . Chronic alcohol consumption . Hepatomegaly , right upper quadrant abdominal pain tenderness . Any chronic drug treatment , include treatment immunosuppressive drug , investigator 's opinion , preclude inclusion study . History allergic disease likely stimulate component vaccine . Simultaneous participation clinical trial . Previous vaccination hepatitis B vaccine . Previous vaccination MPL contain vaccine . Administration immunoglobulins past 3 month whole study period Vaccination one month one month dose study vaccine</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>HBV-MPL</keyword>
	<keyword>Recombinant Hepatitis B vaccine</keyword>
</DOC>